T1	Pharmacodynamic_phenotype	52 72	erlotinib -sensitive
T2	Limited_variation	73 91	EGFR -mutant NSCLC
T3	Disease	73 96	EGFR -mutant NSCLC cell
T4	Chemical	152 167	platinum agents
T5	Chemical	200 222	chemotherapy treatment
T6	Pharmacodynamic_phenotype	248 271	response to erlotinib .
R1	influences	Arg1:T1	Arg2:T2
R2	influences	Arg1:T1	Arg2:T3
R3	influences	Arg1:T1	Arg2:T4
R4	influences	Arg1:T1	Arg2:T5
R5	influences	Arg1:T1	Arg2:T6
R6	isEquivalentTo	Arg1:T2	Arg2:T1
R7	isAssociatedWith	Arg1:T2	Arg2:T3
R8	influences	Arg1:T2	Arg2:T4
R9	influences	Arg1:T2	Arg2:T5
R10	influences	Arg1:T2	Arg2:T6
R11	isAssociatedWith	Arg1:T3	Arg2:T1
R12	isAssociatedWith	Arg1:T3	Arg2:T2
R13	influences	Arg1:T3	Arg2:T4
R14	influences	Arg1:T3	Arg2:T5
R15	influences	Arg1:T3	Arg2:T6
R16	influences	Arg1:T4	Arg2:T1
R17	influences	Arg1:T4	Arg2:T2
R18	influences	Arg1:T4	Arg2:T3
R19	influences	Arg1:T4	Arg2:T5
R20	influences	Arg1:T4	Arg2:T6
R21	influences	Arg1:T5	Arg2:T1
R22	influences	Arg1:T5	Arg2:T2
R23	treats	Arg1:T5	Arg2:T3
R24	influences	Arg1:T5	Arg2:T4
R25	influences	Arg1:T5	Arg2:T6
R26	influences	Arg1:T6	Arg2:T1
R27	influences	Arg1:T6	Arg2:T2
R28	treats	Arg1:T6	Arg2:T3
R29	influences	Arg1:T6	Arg2:T4
R30	influences	Arg1:T6	Arg2:T5
